<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04848597</url>
  </required_header>
  <id_info>
    <org_study_id>CUP-002</org_study_id>
    <nct_id>NCT04848597</nct_id>
  </id_info>
  <brief_title>PD-1 Inhibitor and Nab-paclitaxel and Bevacizumab in CUP</brief_title>
  <official_title>Phase 2, Open-label, Single Center, Prospective Study of Recombinant Humanized Anti-PD-1 Monoclonal Antibody Combined With Nab-paclitaxel and Bevacizumab in the Second-line Treatment of Patients With Cancer of Unknown Primary (CUP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is a single-center, prospective, single-arm Phase II clinical study. The purpose&#xD;
      is to evaluate the efficacy and safety of recombinant humanized anti-PD-1 monoclonal antibody&#xD;
      combined with albumin paclitaxel and bevacizumab in the second-line treatment of patients&#xD;
      with unknown primary tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recombinant humanized anti-PD-1 monoclonal antibody combined with albumin paclitaxel and&#xD;
      bevacizumab treatment, once every 3 weeks, treatment until disease progression, intolerable&#xD;
      adverse reactions, patient death or withdrawal informed agree.After treatment, the patients&#xD;
      was followed up every 9 weeks for follow-up treatment and survival.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2021</start_date>
  <completion_date type="Anticipated">May 3, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>objective response rate (ORR) was assessed using RECIST1.1 and IRECIST standards.</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>ORR is defined as CR+PR</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Cancer of Unknown Primary</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recombinant humanized anti-PD-1 monoclonal antibody injection:200mg once every 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant humanized anti-PD-1 monoclonal antibody injection</intervention_name>
    <description>200mg , once every 3 weeks</description>
    <arm_group_label>Single Arm</arm_group_label>
    <other_name>Albumin Paclitaxel</other_name>
    <other_name>bevacizumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The histopathologically confirmed metastasis is adenocarcinoma, squamous cell&#xD;
             carcinoma, poorly differentiated carcinoma, poorly differentiated malignant tumor or&#xD;
             neuroendocrine carcinoma;&#xD;
&#xD;
          2. Patients whose primary lesions cannot be found after standard evaluation prior to&#xD;
             treatment: detailed history, physical examination, blood test, chest and pelvic CT,&#xD;
             PET/CT (optional), endoscopy of symptomatic sites, and pathological examination;&#xD;
&#xD;
          3. Measurable lesions (RECIST 1.1 criteria);&#xD;
&#xD;
          4. Patients who have progressed after receiving first-line treatment for Carcinoma of&#xD;
             Unknown Primary. For example, those who have received paclitaxel or docetaxel in the&#xD;
             first-line treatment and progressed more than three months after the end of last&#xD;
             treatment;&#xD;
&#xD;
          5. ECOG of 0-2;&#xD;
&#xD;
          6. Life expectancy&gt;3 months;&#xD;
&#xD;
          7. Within 7 days (including 7 days) before screening, the laboratory test data&#xD;
             requirements: neutrophil count ≥1.5×10^9/L, platelet count ≥90×10^9/L, hemoglobin&#xD;
             ≥90g/L (No blood transfusion in 14 days), serum total bilirubin ≤1.25 times the upper&#xD;
             limit of normal (ULN); ALT and AST≤2.5 x ULN (patients with liver metastases ≤5x ULN);&#xD;
             serum creatinine ≤1.25 x ULN&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who have previously been treated with albumin paclitaxel or bevacizumab or&#xD;
             PD-1 monoclonal antibody;&#xD;
&#xD;
          2. Received any experimental drugs or anti-tumor drugs within 4 weeks prior to&#xD;
             enrollment;&#xD;
&#xD;
          3. A history of other tumors in the past 5 years, except for cervix or basal cell&#xD;
             carcinoma of the skin that has been cured;&#xD;
&#xD;
          4. Symptomatic brain or meningeal metastases (unless the patient receives treatment for&gt;&#xD;
             6 months, the imaging results are negative within 4 weeks before entering the study,&#xD;
             and the clinical symptoms related to the tumor are stable at the time of entering the&#xD;
             study).&#xD;
&#xD;
        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xichun Hu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xichun Hu, MD, PhD</last_name>
    <phone>64175590</phone>
    <phone_ext>85006</phone_ext>
    <email>xchu2009@hotmail.com</email>
  </overall_contact>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 14, 2021</study_first_submitted>
  <study_first_submitted_qc>April 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2021</study_first_posted>
  <last_update_submitted>April 14, 2021</last_update_submitted>
  <last_update_submitted_qc>April 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Xichun Hu</investigator_full_name>
    <investigator_title>Director of department of medical oncology</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

